Comparisons of the actions of high and low doses of the MAO inhibitor tranylcypromine on 5-HT2 binding sites in rat cortex

  • D. B. Goodnough
  • G. B. Baker
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 41)


Tranylcypromine (TCP) is a commercially available antidepressant drug, and recent literature reports suggest that high doses of this drug may be particularly effective in treating refractory depression. Down-regulation of 5-HT2 receptors in rat cortex is an effect produced after chronic administration of several antidepressants, and we have conducted a chronic study comparing low- and high-dose TCP in this regard. Male Sprague-Dawley rats were administered TCP (0.5 or 2.5 mg/kg/day) or vehicle (distilled water) via Alzet minipumps implanted subcutaneously in the dorsal thoracic area. Groups of rats were killed 4, 10 or 28 days after pump implantation and whole cortex was dissected out and utilized for preparation of a membrane fraction. Binding studies were performed with this fraction using 3H-ketanserin as the radioligand. Down-regulation (decrease in Bmax) of the 5-HT2 binding site was observed in high-dose animals after 10 and 28 days but not after 4 days. Low-dose TCP had no effect on 5-HT2 densities at any time interval. The affinity of 3H-ketanserin for the 5-HT2 site was not affected by either dose at any time interval. These results suggest that down-regulation of the 5-HT2 site may contribute to the efficacy of high-dose TCP in the treatment of refractory depression.


Monoamine Oxidase Inhibitor Drug Treatment Group Antidepressant Efficacy Refractory Depression Bioi Psychiatry 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amsterdam JD, Berwish NJ (1989) High dose tranylcypromine treatment for refractory depression. Pharmacopsychiatry 22: 21–25.PubMedCrossRefGoogle Scholar
  2. Baker GB, Hiob LE, Dewhurst WG (1980) Effects of monoamine oxidase inhibitors on release of dopamine and 5-hydroxytrypamine from rat striatum in vitro. Cell Mol Biol 26: 182–186.Google Scholar
  3. Baker GB, McKim HR, Calverley DG, Dewhurst WG (1978) Effects of the monoamine oxidase inhibitors tranylcypromine, phenelzine, and pheniprazine of the uptake of catecholamines in slices from rat brain regions. Proc Eur Soc Neurochem 1: 536.Google Scholar
  4. Baker GB, Coutts RT, Rao TS (1987) Neuropharmacological and neurochemical properties of N-(cyanoethyl)-2-phenethylamine, a prodrug of 2-phenethylamine. Br J Pharmacol 92: 243–255.PubMedGoogle Scholar
  5. Baker GB, Greenshaw AJ (1989) Effects of long-term administration of antidepressants on receptors in the central nervous system. Cell Mol Biol 9: 1–44.Google Scholar
  6. Eison AS, Yocca FD, Gianutsos G (1991) Effect of chronic administration of antidepressant drugs on 5-HT2-mediated behavior in the rat following noradrenergic or serotonergic devervation. J Neural Transm 84: 19–32.CrossRefGoogle Scholar
  7. Ferris RM, Howard JL, White HL (1975) A relationship between clinical efficacy and various biochemical parameters of monoamine oxidase inhibitors (MAOIs). Pharmacologist 17: 451.Google Scholar
  8. Giller EG, Lieb J (1980) Monoamine oxidase inhibitors and platelet monoamine oxidase inhibition. Comm Psychopharmacol 4: 79–82.Google Scholar
  9. Giller EG, Bialos D, Riddle M, Sholomskas A, Harkness L (1982) Monoamine oxidase inhibitor-responsive depression. Psychiatry Res 6: 41–48.PubMedCrossRefGoogle Scholar
  10. Goodnough DB, Baker GB (1993) Tranylcypromine does not enhance the effects of amitriptyline on 5-HT2 receptors in rat brain. J Pharm Sci (in press).Google Scholar
  11. Goodnough DB, Baker GB, Mousseau DD, Greenshaw AJ, Dewhurst WG (1994) Effects of low-and high-dose tranylcypromine on [3H]-tryptamine binding sites in the rat hippocampus and striatum. Neurochem Res (in press).Google Scholar
  12. Goodwin GM, Green AR, Johnson P (1984) 5-HT2 receptor changes in frontal cortex and 5-HT2-mediated head-twitch behavior following antidepressant treatment to mice. Br J Pharmacol 83: 235–242.PubMedGoogle Scholar
  13. Greenshaw AJ, Nazarali AJ, Rao TS, Baker GB, Coutts RT (1988) Chronic tranylcypromine treatment induces functional α2-adrenoreceptor down-regulation in rats. Eur J Pharmacol 154: 67–72.PubMedCrossRefGoogle Scholar
  14. Guze BH, Baxter LR, Jr (1987) Refractory depression treated with high doses of a monoamine oxidase inhibitor. J Clin Psychiatry 48: 31–32.PubMedGoogle Scholar
  15. Hendley ED, Snyder SH (1968) Relationship between the action of monoamine oxidase inhibitors on the noradrenaline uptake system and their antidepressant efficacy. Nature 220: 1330–1331.PubMedCrossRefGoogle Scholar
  16. Kellar KJ, Cascio CS, Butler JA, Kurtze RN (1981) Differential effects of electro-convulsive shock and antidepressant drugs on serotonin-2 receptors in rat brain. Eur J Pharmacol 69: 515–518.PubMedCrossRefGoogle Scholar
  17. Lafaille F, Welner SA, Suranyi-Casotte BE (1991) Regulation of serotonin type 2 (5-HT2) and β-adrenergic receptors in rat cerebral cortex following novel and classical antidepressant treatment. J Psychiatr Neurosci 16: 209–214.Google Scholar
  18. Leysen JE, Niemegeers CJE, Van Neuten JM, Laduron P (1982) 3H-Ketanserin (R41468), a selective 3H-ligand for serotonin-2 receptor binding sites. Mol Pharmacol 21: 301–314.PubMedGoogle Scholar
  19. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ (1951) Protein measurements with the Folin phenol reagent. J Biol Chem 193: 265–275.PubMedGoogle Scholar
  20. Mousseau DD, McManus DJ, Baker GB, Juorio AV, Dewhurst WG, Greenshaw AJ (1993) Effects of age and of chronic antidepressant treatment on 3H-tryptamine binding to rat cortical membranes. Cell Mol Neurobiol 13: 3–13.PubMedCrossRefGoogle Scholar
  21. Nazarali AJ, Baker GB, Coutts RT, Yeung JM, Rao TS (1987) Rapid analysis of ß-phenethylamine in tissues and body fluids utilizing pentaflourobenzoylation followed by electron-capture gas chromatography. Prog Neuropsychopharmacol Biol Psychiatry 11: 251–258.PubMedCrossRefGoogle Scholar
  22. Pearlman C (1987) High dose tranylcypromine in refractory depression. J Clin Psychiatry 48: 424.PubMedGoogle Scholar
  23. Reigle TG, Orsulak PJ, Avni J, Platz PA, Schildkraut JJ (1980) The effects of tranylcypromine isomers on 3H-norepinephrine metabolism in rat brain. Psychopharmacology 69: 193–199.PubMedCrossRefGoogle Scholar
  24. Robinson DS, Nies A, Ravaris CL, Ives JO, Barlett D (1978) Clinical pharmacology of phenelzine: MAO activity and clinical response. In: Lipton M, Dimascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York.Google Scholar
  25. Robinson DS (1983) High-dose monoamine oxidase-inhibitor therapy. J Am Med Assoc 250: 2212.Google Scholar
  26. Schildkraut JJ (1970) Tranylcypromine: effects on norepinephrine metabolism in rat brain. Am J Psychiatry 126: 925–931.PubMedGoogle Scholar
  27. Sherry-McKenna RL, Baker GB, Mousseau DD, Coutts RT, Dewhurst WG (1992) 4-Methoxytranylcypromine, a monoamine oxidase inhibitor: effects on biogenic amines in rat brain following chronic administration. Biol Psychiatry 31: 881–888.PubMedGoogle Scholar
  28. Wurtman RJ, Axelrod J (1963) A sensitive and specific assay for the estimation of monoamine oxidase. Biochem Pharmacol 12: 1439–1441.PubMedCrossRefGoogle Scholar
  29. Yates M, Leake A, Candy JM, Fairbairn AF, McKeith IG, Ferrier IN (1990) 5-HT2 receptor changes in major depression. Biol Psychiatry 27: 489–496.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • D. B. Goodnough
    • 1
    • 2
  • G. B. Baker
    • 2
  1. 1.Neurochemical Research Unit, Department of PsychiatryUniversity of AlbertaEdmontonCanada
  2. 2.Neurochemical Research Unit, Department of Psychiatry1E7.44 W Mackenzie Health Sciences CentreEdmontonCanada

Personalised recommendations